**Supplementary Table 4. Study quality and risk of bias from each study for CHB patients with positive HBeAg**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Confounding** | **Measurement of the exposure** | **Selection of participants** | **Post-exposure interventions** | **Missing data** | **Measurement of outcomes** | **Selection of the reported result** | **Overall Risk** |
| Schwarz KB, 2019 | Some concerns | Low | Low | Low | Some concerns | Low | Low | Some concerns |
| Demirören K, 2015 | Some concerns | Low | Low | Low | Low | Low | Low | Low |
| Elbir P, 2014 | Some concerns | Low | Low | Low | Low | Low | Low | Low |
| Larsson SB, 2014 | Some concerns | Low | Low | Low | Low | Low | Low | Low |
| Mao QG, 2010 | Some concerns | Low | Low | Low | Low | Low | Low | Low |
| Shao J, 2007 | Some concerns | Low  | Low | Low | Low | Low | Low | Low |
| Keun ChunY, 2000 | Some concerns | Low | Low | Low | Some concerns | Low | Low | Some concerns |

CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; ALT, alanine aminotransferase.